← FDA DRUG APPROVALS

FDA NDA · NDA215029

BONDLIDO

lidocaine

Sponsor: MEDRX USA

APPLICATION
NDA215029
TYPE
NDA
ORIGINAL APPROVAL
2025-09-24
LATEST ACTION
2025-09-24
ROUTE
TOPICAL
DOSAGE FORM
SYSTEM
MARKETING STATUS
Prescription

Products

BONDLIDO · ReferencePrescription
LIDOCAINE 10% · SYSTEM · TOPICAL

Approval history

2025-09-24Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →